Oragenics (NYSEAMERICAN:OGEN) Trading Down 1.5% – Here’s Why

Oragenics, Inc. (NYSEAMERICAN:OGEN) dropped 1.5% on Monday . The stock traded as low as $0.54 and last traded at $0.5411. 8,676 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 30,866 shares. The stock had previously closed at $0.5496.

Oragenics Price Performance

The stock has a 50 day moving average price of $0.59 and a 200-day moving average price of $0.69. The stock has a market capitalization of $2.44 million, a price-to-earnings ratio of -0.03 and a beta of 1.25.

Oragenics (NYSEAMERICAN:OGEN) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.51) EPS for the quarter.

Institutional Investors Weigh In On Oragenics

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in shares of Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares in the last quarter. XTX Topco Ltd acquired a new position in Oragenics during the fourth quarter worth about $26,000. Finally, DRW Securities LLC grew its stake in Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after acquiring an additional 50,900 shares in the last quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.